Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Effects on Lipids of 12 Weeks of 2 Doses of FM-VP4 in Subjects With Primary Hypercholesterolemia

The purpose of this study is to evaluate the safety and effects on lipids of FM-VP4 administered for 12 weeks in subjects with mild to moderate primary hypercholesterolemia.

Inclusion Criteria:

• Mild to moderate primary hypercholesterolemia
• Able to give informed consent and to comply with study procedures (including diet)

Exclusion Criteria:

• Homozygous familial hypercholesterolemia
• Age <18 or >75 years
• Pregnant women or women of child-bearing potential